Technical Analysis for RCUS - Arcus Biosciences, Inc.
ADX | Long Term | Intermediate Term | Short Term |
---|---|---|---|
Strong | Down | Flat | Down |
Date | Alert Name | Type | % Chg |
---|---|---|---|
Fell Below 20 DMA | Bearish | 0.00% | |
Fell Below 200 DMA | Bearish | 0.00% | |
Crossed Above 20 DMA | Bullish | -9.27% | |
Pocket Pivot | Bullish Swing Setup | -9.27% | |
Fell Below 20 DMA | Bearish | -6.00% | |
200 DMA Support | Bullish | -6.00% | |
Gapped Down | Weakness | -6.00% | |
NR7 | Range Contraction | -9.61% | |
Inside Day | Range Contraction | -7.62% | |
Wide Bands | Range Expansion | -7.62% |
Alert | Time |
---|---|
60 Minute Opening Range Breakdown | about 15 hours ago |
Fell Below 200 DMA | about 15 hours ago |
200 DMA Support | about 16 hours ago |
Down 5% | about 16 hours ago |
Fell Below Previous Day's Low | about 16 hours ago |
Get this analysis on your stocks daily!
- Earnings date: 02/26/2024
Arcus Biosciences, Inc. Description
Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, engages in developing and commercializing cancer immunotherapies in the United States. The company develops various programs targeting immuno-oncology pathways, including AB928, a dual adenosine receptor antagonist, which is in a Phase I/Ib clinical trial; and AB122, an anti-PD-1 antibody that is in Phase I clinical trial. It is also developing AB154, an anti-T-cell immunoreceptor with Ig and ITIM domains antibody, which is in Phase I trial as monotherapy; and AB680, a small-molecule inhibitor of CD73 that is in Phase I healthy volunteer study. The company has a clinical development collaboration agreement with Strata Oncology, Inc. to evaluate AB122, an anti-PD-1 antibody. Arcus Biosciences, Inc. was founded in 2015 and is headquartered in Hayward, California.
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Medicine Biopharmaceutical Cancer Clinical Medicine Clinical Development Cancer Treatment Cancer Immunotherapy Monoclonal Antibodies Immunotherapies Adenosine Cd73 Pd 1
Indicator | Bull Case | Neutral / Hold | Bear Case |
---|---|---|---|
50 DMA | |||
200 DMA | |||
ADX Trend | |||
Oversold / Overbought | |||
Relative Strength |
Indicator | Value |
---|---|
52 Week High | 25.47 |
52 Week Low | 12.96 |
Average Volume | 917,553 |
200-Day Moving Average | 18.04 |
50-Day Moving Average | 17.15 |
20-Day Moving Average | 18.69 |
10-Day Moving Average | 18.53 |
Average True Range | 1.03 |
RSI (14) | 45.05 |
ADX | 25.68 |
+DI | 20.88 |
-DI | 20.09 |
Chandelier Exit (Long, 3 ATRs) | 17.21 |
Chandelier Exit (Short, 3 ATRs) | 19.03 |
Upper Bollinger Bands | 20.65 |
Lower Bollinger Band | 16.72 |
Percent B (%b) | 0.13 |
BandWidth | 20.99 |
MACD Line | 0.35 |
MACD Signal Line | 0.54 |
MACD Histogram | -0.1898 |
Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
---|---|---|---|---|---|
Resistance 4 (R4) | 19.95 | ||||
Resistance 3 (R3) | 20.23 | 19.61 | 19.50 | ||
Resistance 2 (R2) | 19.61 | 18.91 | 19.47 | 19.34 | |
Resistance 1 (R1) | 18.41 | 18.48 | 18.10 | 18.13 | 19.19 |
Pivot Point | 17.79 | 17.79 | 17.63 | 17.65 | 17.79 |
Support 1 (S1) | 16.59 | 17.09 | 16.28 | 16.31 | 15.25 |
Support 2 (S2) | 15.97 | 16.66 | 15.83 | 15.10 | |
Support 3 (S3) | 14.77 | 15.97 | 14.95 | ||
Support 4 (S4) | 14.49 |